Efficient Suppression of Minority Drug-Resistant HIV Type 1 (HIV-1) Variants Present at Primary HIV-1 Infection by Ritonavir-Boosted Protease Inhibitor-Containing Antiretroviral Therapy by Metzner, Karin J. et al.
Suppression of Minor Drug-Resistant HIV • JID 2010:201 (1 April) • 1063
M A J O R A R T I C L E
Efficient Suppression of Minority Drug-Resistant HIV
Type 1 (HIV-1) Variants Present at Primary HIV-1
Infection by Ritonavir-Boosted Protease Inhibitor–
Containing Antiretroviral Therapy
Karin J. Metzner,1,3 Pia Rauch,3 Viktor von Wyl,1 Christine Leemann,1 Christina Grube,1 Herbert Kuster,1 Ju¨rg Bo¨ni,2
Rainer Weber,1 and Huldrych F. Gu¨nthard1
1Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, and 2Swiss National Center for Retroviruses, University
of Zurich, Zurich, Switzerland; and 3Institute of Clinical and Molecular Virology, University of Erlangen-Nuremberg, Germany
Background. Selection of preexisting minority variants of drug-resistant human immunodeficiency virus type
1 (HIV-1) can lead to virological failure in patients who receive antiretroviral therapy (ART) with low genetic
resistance barriers. We studied treatment response and dynamics of minority variants during the first weeks of
ART containing a ritonavir–boosted protease inhibitor (PI) and 2 nucleoside reverse-transcriptase inhibitors
(NRTIs), which is a regimen with a high genetic resistance barrier.
Methods. Plasma samples obtained prior to initiation of ART from 109 patients with primary HIV infection
and samples obtained during viral decay during early ART from 17 of these 109 patients were tested by allele-
specific polymerase chain reaction for K103N and M184V variants.
Results. K103N and/or M184V mutations were detected in 15 (13.8%) of 109 patients prior to ART as minority
variants. No selection of these variants was observed within the first weeks of ART in 7 of 15 patients with
preexisting drug resistance mutations, nor was any selection observed in 10 patients without preexisting drug
resistance mutations. Most patients received ART immediately after diagnosis of HIV-1 infection, showed a rapid
decrease in viral load, and experienced sufficient suppression of viremia for 48 months.
Conclusions. Minority variants, in particular viruses harboring the M184V mutation, were efficiently suppressed
in patients with acute infection who received a ritonavir-boosted PI and 2 NRTIs (most regimens included
lamivudine). Under this high genetic resistance barrier regimen, the M184V was not further selected.
The reduction of morbidity and mortality among pa-
tients with human immunodeficiency virus type 1
(HIV-1) infection is one of the major achievements in
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the treatment of infectious diseases [1]. Moreover, the
approval of new drugs within the already broad range
of reverse-transcriptase inhibitors and protease inhib-
itors (PIs) and new drug classes are constantly increas-
ing treatment options [2]. However, eradication of
HIV-1 is not feasible with current regimens [3–5]; thus,
development of drug-resistant viruses is still a major
concern. Virological failure limits further treatment
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options because of cross-resistance and persistence of drug-
resistant viruses [6, 7].
Because of possible transmission of drug-resistant viruses [8–
12], it is recommended to perform resistance testing before
initiation of antiretroviral therapy (ART) [13], because pre-
existing drug-resistant viruses can lead to therapy failure when
they represent the majority of viral variants [14, 15]. Resistance
testing is usually performed using population sequencing,
which does not allow detection of drug-resistant virus popu-
lations representing less than 20%–25% of the variants [16,
17]. Allele-specific real-time PCR (AS-PCR) can bridge this gap
by allowing the detection of minority variants with discrimi-
natory abilities as low as 0.01% [18].
We and others have shown that minority drug-resistant HIV-
1 variants can be detected despite the absence of drug resistance
mutations by population sequencing. This was clearly dem-
onstrated in women after treatment with single-dose nevirapine
to prevent mother-to-child transmission [19, 20], in acute se-
roconverters [21, 22], and in patients undergoing structured
treatment interruptions [23]. Furthermore, it was shown that
preexisting minority drug-resistant variants can lead to viro-
logical failure in treatment-experienced patients [24–27]. How-
ever, the impact of these drug-resistant viruses at low frequen-
cies in treatment-naive patients initiating ART is still contro-
versial. Several studies did not observe a correlation between
their presence prior to ART and virological failure, and other
studies reported a correlation, especially in the context of ART
regimens with a low genetic resistance barrier [22, 28–35].
These diverse observations might be caused by differences with
regard to the methodology used and their discriminatory abil-
ities, patient populations (eg, patients with acute or recent in-
fection vs those with long-term infection), follow-up periods,
and antiretroviral regimens chosen for first-line treatment dis-
playing dissimilarities in genetic resistance barriers.
Here, we investigated a possible correlation between the clin-
ical outcome of ART regimens with a high genetic resistance
barrier containing a ritonavir–boosted PI, together with 2 nu-
cleoside reverse-transcriptase inhibitors (NRTIs) and the pres-
ence of minority drug-resistant HIV-1 variants in a group of
109 patients with acute HIV-1 infection from the Zurich pri-
mary HIV-1 infection study (ZPHI) prior to ART by AS-PCR
for the K103N and M184V variants. Furthermore, possible early
selection of drug-resistant viruses was measured by AS-PCR
for the K103N and M184V variants in longitudinal plasma
samples of the first weeks of ART of 17 patients harboring and
patients not harboring drug-resistant viruses at low frequencies
prior to ART.
METHODS
Study design and patients. Plasma samples from 109 patients
from the ZPHI cohort were obtained from March 2002 through
December 2007 from edetic acid blood samples collected 0–19
days before initiation of ART. For 17 of 109 patients, 1–4 plasma
samples per patient were collected during viral decay within
the first 16 weeks of ART. The ZPHI study is an observational,
open label, nonrandomized, single-center study (ClinicalTrials
.gov identification no. NCT00537966). Patients with acute and
recent HIV-1 infection are included. Acute HIV-1 infection is
defined as (1) presentation of the acute retroviral syndrome
(ARS) and negative or indeterminate Western-blot test results
in the presence of a positive p24 antigen test result and/or
detectable viral load or (2) documented seroconversion with
or without symptoms within 90 days. Recent infection is de-
fined as (1) possible ARS, a positive Western-blot test result,
detectable viral load, and a negative HIV gp120 avidity re-
spectively detuned assay result [36] or (2) documented acute
HIV-1 infection with referral to our center 190 days after pre-
sumed date of infection. Patients are offered early ART and,
after 1 year of suppressed viremia (!40 HIV-1 RNA copies/mL
of plasma), patients can chose to interrupt ART. Written in-
formed consent was obtained from each patient prior to in-
clusion. Clinical follow-up data for the patients until December
2008 have been analyzed. Thus, all patients had 12 months
of follow-up.
HIV quantification and resistance testing. Plasma HIV-1
RNA was quantified using the Cobas AmpliPrep/Cobas TaqMan
HIV-1 test (Roche Diagnostics) with a limit of 40 HIV-1 RNA
copies/mL of plasma. Resistance testing by population sequenc-
ing was performed using the Viroseq vs 1 (PE Biosystems) or
Viroseq vs 2 (Abbott). Drug resistance mutations were defined
as recommended by the International AIDS Society–USA Drug
Resistance Mutations Group and the surveillance drug resis-
tance mutations list [13, 37].
AS-PCR for detection and quantification of minority drug-
resistant HIV-1 variants harboring K103N and/or M184V
mutations. Viral RNA from 1 mL of plasma was analyzed
retrospectively by AS-PCR quantifying minority variants of vi-
ruses harboring the K103N or the M184V mutation. Processing
of plasma, reverse transcription, first amplification, the K103N
and M184V AS-PCR assays, and the data analysis have been
described elsewhere [21, 23]. The K103N AS-PCR has been
further validated in a blinded, multicenter comparison of meth-
ods detecting minority variants [38]. The discriminatory abil-
ities of the K103N and M184V AS-PCR assays are 0.01% and
0.2% for the respective mutant. Because the discriminatory
ability is not only dependent on the limitations of each AS-
PCR assay but also on the viral load, individual cutoff values
were calculated on the basis of viral load, as described elsewhere
[23].
Reverse-transcriptase sequences were individually checked
on the basis of data obtained by population sequencing with
regard to primer binding sites for all patients infected with
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HIV-1 subtype non-B. Patients were not included in this study
when 13 mutations were observed within 1 primer binding site
of the primers used for the first amplification or of the primer
used for the reverse transcription. In addition, total copy num-
bers obtained by AS-PCR had to be in due proportion to the
corresponding viral load from the same time point. Outliers
have been excluded from final analyses. All samples were re-
peated when 1 or both mutations were detected at low fre-
quencies. Furthermore, each run, in addition to standard di-
lutions and no template master mix samples, contained 4
controls: (1) 107 DNA copies of wild-type and mutant standard
separately amplified with the respective incorrect allele-specific
primer to control the discriminatory ability of each AS-PCR
run; (2) 10.000 HIV-1 NL4–3 wild-type RNA copies in 1 mL
plasma of an HIV-1 negative donor (wild-type control); (3)
mixture of 9.900 HIV-1 NL4–3 wild-type RNA copies plus 100
HIV-1 NL4–3K103N+M184V RNA copies in 1 mL of plasma of an
HIV-1–negative donor (1% mutant control); and (4) 1 mL of
plasma of an HIV-1–negative donor (negative control). Each
time, 13 plasma samples from patients and the controls were
processed in parallel, starting with RNA isolation, and measured
in the same K103N and M184V AS-PCR runs. Performance of
DNA standard dilutions and controls of each AS-PCR were
compared with previously performed AS-PCR assays. Thus far,
1100 AS-PCR runs regarding each of the mutations K103N and
M184V have been performed. The complete run was repeated
when, for example, 1 standard was out of range.
Statistical analysis. The impact of the presence of minority
drug-resistant HIV-1 variants at baseline was statistically as-
sessed using the 2-tailed Wilcoxon rank-sum test for contin-
uous data and the 2-tailed Fisher’s exact test or x2 test for
categorical data. Statistical analyses were performed using the
software Prism5 (GraphPad Software). P values !.05 were re-
garded as statistically significant.
RESULTS
Drug resistance mutations at low frequencies in primary HIV-
1 infection prior to ART. All patients are asked to participate
in the ZPHI study who are seen in our outpatient clinic and
private practices in Zurich, Switzerland, who show clinical signs
and have diagnostic values that indicate acute or recent infec-
tion. From January 2002 through December 2007, 164 patients
were consecutively included in the ZPHI study, of whom 50
patients were not eligible for the retrospective analysis of drug
resistance mutations at low frequencies because of the following
reasons: the HIV-1 genotype revealed too many mismatches in
the primer binding sites for the AS-PCR assays (27 patients
with HIV-1 subtype non-B), no plasma sample was available
that had been obtained prior to ART initiation (15 patients),
the patient dropped out of the study (5 patients), or the pres-
ence of chronic HIV-1 infection was detected at the time of
entry into the study (3 patients). Thus, AS-PCR assays were
performed using plasma samples from 114 patients. Samples
from 5 patients were repeatedly classified as outliers because
of no amplification or amplification that was too weak. The
number of mismatches between HIV-1 genotype and oligo-
nucleotides could not explain the outliers (4 patients were in-
fected with HIV-1 subtype B). No obvious reason for these
outliers could be determined; however, these 5 patients were
excluded from the final analyses.
The presence of minority variants of K103N-harboring and
M184V-harboring viruses was measured by AS-PCR in plasma
samples from 109 patients with primary HIV-1 infection prior
to ART initiation. Neither of these 2 mutations were detected
by resistance testing using population sequencing in any of
these patients. In 4 patients (3.7%), major drug resistance mu-
tations were detected by population sequencing (M41L and
L210W [reverse transcriptase]; L90M [protease]; M46L [pro-
tease]; and D67N [reverse transcriptase]). Treatment failure was
not observed in these patients.
AS-PCR was applied to the earliest available plasma samples
with regard to diagnosis of HIV-1 infection. In the majority of
patients who initiated ART, the plasma sample was obtained
on the same day that early ART was initiated. The K103N
mutation was detected in 6 (5.5%) of 109 patients at frequencies
of 0.08%–3.76% (Table 1). In 11 (10.1%) of 109 patients, the
M184V mutation was found as minority variants representing
0.4%–8.3% of plasma viral genomes (Table 1). In 2 patients,
both mutations were detected. In total, viruses obtained from
15 (13.8%) of 109 patients harbored the K103N and/or the
M184V mutations at low frequencies. All patients were offered
early ART containing a ritonavir-boosted PI and 2 NRTIs as
standard regimen at their first visit; thus, the decision was not
based on the HIV-1 genotype. Only 2 patients received initial
therapy with 1 nonnucleoside reverse-transcriptase inhibitor
(NNRTI) and 2 NRTIs, because they wished to receive a once-
daily regimen. Both patients switched to a ritonavir-boosted
PI plus 2 NRTIs within the first weeks of ART because of ad-
verse effects. When patients declined to initiate early ART, they
could still participate in the ZPHI cohort as untreated control
patients.
Comparison of patients harboring and patients not har-
boring minority drug-resistant HIV-1. Both groups were
compared with regard to sex, age, route of transmission, pres-
ence of ARS, acute and recent infection, CD4+ cell count and
HIV-1 RNA copy numbers at baseline, HIV-1 subtype, and drug
resistance, as detected by population sequencing. None of these
parameters were significantly different between the groups (Ta-
ble 2). The majority of patients were men who have sex with
men and were infected with HIV-1 subtype B. ARS was diag-
nosed in 185% of patients, and acute HIV-1 infection was
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Table 1. Detection of Minority Variants of K103N and M184V Viruses in 15 of 109 Patients with Primary Human Immunodeficiency
Virus Type 1 (HIV-1) Infection Prior to Antiretroviral Therapy
Patient no. Sex
Route of
infection
HIV-1
subtype
Year of
primary
HIV-1
infection
HIV-1 RNA level,
copies/mL of plasma
Allele-specific real-time PCR
Drug resistance
mutations by GRT
First- line
treatment
K103N,
mean % (SD)
M184V,
mean % (SD)
28023 M MSM B 2002 11,000 !LLD 2.4  1.1 None LPV/r, AZT, 3TC
108 M MSM B 2003 3560 !LLD 1.0  0.1 None LPV/r, AZT, 3TC
109 M MSM B 2003 55,200 !LLD 1.3  0.1 None LPV/r, AZT, 3TC
115 M MSM B 2003 6040 0.91  0.24 1.0  0.0 None LPV/r, AZT, 3TC
121 M MSM B 2003 1550 !LLD 2.1  0.2 None LPV/r, AZT, 3TC
123 M MSM B 2003 3,620,000 0.18  0.02 !LLD None LPV/r, AZT, 3TC
131 M MSM B 2004 3,335,000 !LLD 0.4  0.0 None LPV/r, TDF, ddI
135 M MSM B 2004 226,000 0.83  0.30 8.3  2.2 None None
137 M MSM B 2004 87,300 !LLD 0.4  0.0 None LPV/r, AZT, 3TC
162 M MSM B 2005 51,100 !LLD 0.4  0.0 None LPV/r, AZT, 3TC
172 M MSM B 2005 47,900 1.25  0.13 !LLD None LPV/r, AZT, 3TC
177 M MSM B 2005 2,220,000 3.76  0.79 !LLD None LPV/r, AZT, 3TC
179 F Heterosexual sex B 2005 60,900 !LLD 2.1  1.0 None None
194 M MSM B 2006 930,000 !LLD 0.4  0.1 None LPV/r, AZT, 3TC
214 M MSM 06_CPX 2006 52,800 0.08  0.03 !LLD None LPV/r, AZT, 3TC
NOTE. 3TC, lamivudine; AZT, zidovudine; ddI, didanosine; GRT, genotypic resistance testing by population sequencing; LLD, lower limit of detection; LPV/r,
ritonavir-boosted lopinavir; MSM, men who have sex with men; PCR, polymerase chain reaction; TDF, tenofovir.
confirmed in 78.9% of all patients for the time at which the
baseline plasma sample was collected.
No selection of viruses carrying the K103N or M184V mu-
tation during viral decay within the first 16 weeks of ART.
Thirteen of 15 patients who harbored minority drug-resistant
HIV-1 variants started ART during primary HIV-1 infection,
and 2 patients did not receive early ART. Possible selection of
these drug-resistant variants has been investigated by measuring
the K103N and M184V mutations by AS-PCR in longitudinal
plasma samples obtained from 7 of 13 patients who received
early ART within the first weeks after treatment initiation. Be-
cause plasma samples were not suitable for AS-PCR when the
viral load was !300 HIV-1 RNA copies/mL, the remaining 6
patients could not be included because of very rapid decreases
in viral load. In addition, 10 patients without evidence of drug-
resistant viruses at low frequencies at baseline were included
in this study. They were matched to the other 7 patients with
regard to viral load and CD4+ T cell count at baseline, duration
until viral load became undetectable, and time of infection. All
17 patients were male, were infected with HIV-1 subtype B,
and received ritonavir-boosted lopinavir plus zidovudine plus
lamivudine, except for 1 patient who was treated with ritonavir-
boosted lopinavir plus tenofovir plus didanosine. Two patients
had minority K103N-harboring HIV-1 variants before initiation
of ART, which had not been selected during the first weeks. In
patient 177, this variant was efficiently suppressed. At baseline,
13% of viruses carried the K103N mutation, and ∼4 weeks
later, this mutation was undetectable, with a detection limit of
1.4% based on the viral load at this time point (Figure 1). The
M184V mutation was also not selected in any of the 5 patients
who harbored this mutation at low frequencies prior to ART;
however, it must be considered that, at all time points after
initiation of ART, the individually estimated discriminatory
thresholds of the M184V AS-PCR assay were higher than the
frequencies at which the M184V was detected at baseline. For
instance, patient 137 harbored 0.4% M184V viral variants prior
to ART. This variant was not detected at the 2 subsequent time
points with individual cutoff values based on the viral loads of
0.9% and 2.8%. This means that M184V variants could have
been selected up to these individual cutoff values. However,
suppression of viral replication was sufficiently obtained for all
patients, which argues against rapid selection of drug-resistant
viruses. No evidence for the appearance and selection of K103N
or M184V variants was observed in the 10 patients who lacked
these mutations prior to ART (Figure 1).
Long-term follow-up of all patients. The outcome of ART
in both groups of patients was investigated. Eighty-two of 94
patients who did not harbor and 13 of 15 patients who harbored
minority drug-resistant HIV-1 variants at baseline started early
ART (Table 3). Among treated patients, follow-up clinical data
for 12 months was available for all 13 of the patients who
did harbor and 79 of the 82 patients who did not harbor
minority drug-resistant HIV-1 variants at baseline. All patients
received a ritonavir-boosted PI and 2 NRTIs, except 1 patient
who started ART containing efavirenz plus tenofovir plus em-
tricitabine, however, the regimen was changed at week 2.5 by
replacing efavirenz with ritonavir-boosted lopinavir. All patients
were offered the opportunity to interrupt ART after 12 months
of efficient treatment (ie, viral load !40 HIV-1 RNA copies/
mL of plasma for12 months). No significant differences were
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Table 2. Characteristics of Patients with Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Classified with Regard to the Presence of Minority Drug-Resistant HIV-1 Variants Prior to Antiretroviral
Therapy
Clinical parameter
Patients haboring
minority drug-resistant
HIV-1 variants
(np15)
Patients not haboring
minority drug-resistant
HIV-1 variants
(np94) P a
Sex
Male 14 (93.3) 88 (93.6) 1.99
Female 1 (6.7) 6 (6.4)
Age, median years (IQR) 38 (33–42) 35 (30–41) .29
Route of transmission
MSM 14 (93.3) 76 (80.9) .82
Heterosexual sex 1 (6.7) 14 (14.9)
IDU 0 (0.0) 1 (1.1)
MSM or heterosexual sex 0 (0.0) 2 (2.1)
IDU or heterosexual sex 0 (0.0) 1 (1.1)
Acute retroviral syndrome
Yes 12 (80.0) 82 (87.2) .21
No 3 (20.0) 7 (7.4)
ND 0 (0.0) 5 (5.3)
Acute or recent infection
Acute 13 (86.7) 73 (77.7) .53
Recent 2 (13.3) 14 (14.9)
ND 0 (0.0) 7 (7.4)
CD4+ cell count, median cells/mm3 blood (IQR) 488 (346–553) 363 (281–568) .48
HIV-1 RNA level, median log10 copies/mL plasma 4.7 (4.0–6.0) 5.3 (4.7–6.2) .10
HIV-1 subtype
B 14 (93.3) 85 (90.4) 1.99
Non B 1 (6.7) 9 (9.6)
Resistance detected by population sequencing
No 15 (100.0) 90 (95.7) 1.99
Yes 0 (0.0) 4 (4.3)
NOTE. Data are no. (%) of patients, unless otherwise indicated. IDU, injection drug use; IQR, interquartile range; MSM,
men who have sex with men; ND, not determined.
a Statistical analyses were performed using the 2-tailed Wilcoxon rank-sum test for continuous data and the 2-tailed Fisher’s
exact test or x2 test for categorical data.
observed in the percentages of patients interrupting ART or in
the duration of ART until treatment interruption in both
groups (Table 3). Furthermore, the follow-up period for pa-
tients who continued ART was not significantly different be-
tween patients who harbored and those who did not harbor
K103N and/or M814V variants at low frequencies. One patient
experienced treatment failure, defined by an increase in viral
load 140 copies/mL of plasma after achieving !40 copies/mL
at 2 consecutive visits (Table 3). Viremia rapidly decreased
within the first 4 months of ART in this patient; however, in
the following 16 months, viral load fluctuated between 47 and
166 HIV-1 RNA copies/mL of plasma. Viral load was unde-
tectable only once. This patient lacked drug-resistant viruses
according to population sequencing and K103N and M184V
AS-PCR assays that were performed before treatment initiation.
None of the patients who harbored minority drug-resistant
HIV-1 variants prior to ART experienced therapy failure.
DISCUSSION
The ZPHI is a long-term, observational, open label, nonran-
domized, single-center study that was started in 2002. Until the
end of 2007, 1150 patients with acute or recent HIV-1 infection
have been included. We retrospectively measured the presence
of minority drug-resistant HIV-1 variants harboring K103N
and/or M184V mutations using AS-PCR in the earliest available
plasma samples prior to early ART for 109 individuals. None
of these mutations were detected by population sequencing in
samples obtained from any patient. One or both mutations
were detected at low frequencies in 13.8% of patients, and the
M184V mutation was more frequently observed than was the
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Figure 1. Kinetics of viral load and quantification of minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants in patients harboring
and patients not harboring drug-resistant viruses at low frequencies prior to antiretroviral therapy (ART) during the first 16 weeks of ART. HIV RNA
in plasma was measured using the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test (black circles) with a limit of 40 copies/mL of plasma (dashed line).
Allele-specific polymerase chain reaction was used to quantify minority variants of K103N (blue triangles) and M184V (red diamonds) harboring viruses.
The percentage of the virus population carrying the specific mutation was used to calculate the absolute HIV RNA copies/mL of plasma of the drug-
resistant variants on the basis of the corresponding viral load measurement. Percentages ( standard deviations) of each drug-resistant virus population
are given. With regard to each measured plasma sample without detection of K103N (blue open triangles) and M184V (red open diamonds) variants
at low frequencies, discriminatory limits are shown, which have been individually calculated on the basis of the viral load. 3TC, lamivudine; AZT,
zidovudine; ddI, didanosine; LPV/r, ritonavir-boosted lopinavir; TDF, tenofovir.
K103N mutation. This pattern is in accordance with low-fre-
quency prevalence data for primary HIV-1 infection from Ger-
many [21], France [22], and Canada [39].
We have studied the fate of those drug-resistant viruses that
are present at low frequencies during the first weeks of ART.
Minority drug-resistant HIV-1 variants were efficiently sup-
pressed in all patients who harbored these variants prior to
ART and included in this longitudinal analysis. Furthermore,
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Table 3. Antiretroviral Therapy (ART) Regimens, Duration of ART, and Treatment Outcome for Patients with Primary Human
Immunodeficiency Virus Type 1 (HIV-1) Infection Classified with Regard to the Presence of Minority Drug-Resistant HIV-1
Variants Prior to ART
Variable
Patients haboring mi-
nority drug-resistant
HIV-1 variants
(n p 15)
Patients not haboring
minority drug-resistant
HIV-1 variants
(n p 94) P a
Initial ART regimen
2 NRTIs plus RTV-boosted PI 13 (86.7) 80 (85.1) .85
2 NRTIs plus NNRTI 0 (0.0) 2 (2.1)
No ART 2 (13.3) 12 (12.8)
No. of patients receiving ART and followed-up for at least 12
months after initiation of ART 13 79
ART failure
Yes 0/13 (0.0) 1/79 (1.3) 1.99
No 13/13 (100.0) 78/79 (98.7)
Treatment interruption
No 6/13 (46.2) 43/79 (54.4) .77
Yes 7/13 (53.8) 36/79 (45.6)
Duration of ART until treatment interruption, median months (IQR) 14.2 (11.9–17.5) 16.3 (14.1–20.9) .19
Duration of ART for patients without treatment interruption,
median months (IQR) 23.3 (18.6–40.7) 17.4 (13.3–29.0) .20
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; PI,
protease inhibitor.
a Statistical analyses were performed using the 2-tailed Wilcoxon rank-sum test for continuous data and the 2-tailed Fisher’s exact test or x2 test
for categorical data.
neither K103N-harboring nor M184V-harboring viruses were
selected in these 10 patients without evidence for drug-resistant
viruses before treatment initiation. All patients showed rapid
decreases in viral load. The fact that no selection of the M184V
variant occurred in any individual to levels above the cutoff
values based on viral loads, which was, on average, 2.6%, sug-
gests that residual replication is very low or perhaps even com-
pletely inhibited, because the M184V mutation could otherwise
be rapidly and frequently selected (ie, obtain a majority) when
inhibition of viral replication is insufficient. This correlation
was clearly shown for patients who received dual therapy con-
taining lamivudine and ziduvudine [40–42], patients who re-
ceived triple NRTIs [43, 44], and patients who experienced early
therapy failure with 2 NRTIs and 1 NNRTI [33]. Furthermore,
we have previously shown that selection of drug-resistant vi-
ruses within the first weeks of ART, as determined by AS-PCR,
was associated with slow decreases in viremia, which again was
associated with insufficient suppression of viral replication [28].
Thus, potency of ART regimens is one important factor with
regard to the avoidance of early selection of drug-resistant
viruses.
However, it is probably not potency alone that can prevent
the selection of preexisting viruses at low frequencies. We have
recently reported that patients can experience early virological
failure caused by rapid selection of preexisting minority drug-
resistant HIV-1 variants despite the receipt of potent regimens
[33]. Others have also shown that receipt of potent regimens
with low genetic barriers to resistance is associated with viro-
logical failure when drug-resistant viruses are present at low
frequencies prior to ART [30, 34]. Such correlations have not
been observed in patients who received regimens that included
a ritonavir-boosted PI [34] (ie, regimens with a higher genetic
barrier to resistance) [45, 46]. Almost all patients in our study
initiated an ART regimen that contained a ritonavir-boosted
PI. The K103N mutation should have had no impact at all on
such patients. Our data suggest that the M184V mutation as
minor population does not influence the outcome of ART
within the first 12 months in patients who receive a ritonavir-
boosted PI. Ritonavir-boosted PIs have been successfully used
in monotherapy trials, although treatment with ritonavir-
boosted PIs is inferior to treatment with combination ART [47].
This suggests that drug resistance mutations within the reverse
transcriptase might not have a major impact on the clinical
outcome of ART when a ritonavir-boosted PI is part of the
regimen.
It has recently been shown that having 2000 RNA copies/
mL of minority variants harboring the K103N mutation, rather
than the percentage of minority variants harboring the K103N
mutation, is associated with virological failure of NNRTI-con-
taining regimens [48]. In our study, only 3 patients harbored
2000 M184V RNA copies prior to ART. One of these patients
did not start early ART, and another patient was treated with
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ritonavir-boosted lopinavir, tenofovir, and didanosine (a regi-
men not affected by the M184V mutation). The remaining
patient was early treated with ritonavir-boosted lopinavir, zi-
dovudine, and lamivudine and did not experience virological
failure. Nevertheless, it is still unknown whether such a limit
exists in terms of the M184V mutation in the context of ART
containing a ritonavir-boosted PI.
Prediction of virological failure of first-line ART is still not
feasible based on the detection of minority drug-resistant HIV-
1 variants because of controversial data, some of which shows
and some of which does not show an association between the
presence of drug-resistant viruses at low frequencies and vi-
rological failure [22, 28–35]. These diverse observations might
be caused by differences in the discriminatory abilities of dif-
ferent technologies used for detection of minority variants, dif-
ferences in patient populations (those with acute or recent in-
fection vs those with long-term infection), differences in time
periods of follow-up, and differences in antiretroviral regimens
chosen for first-line treatment displaying dissimilarities in ge-
netic resistance barriers and potencies. Furthermore, all studies
have been retrospectively analyzed and included only limited
numbers of patients who experienced virological failure. Before
more-sensitive assays for detection of drug-resistant viruses at
low frequencies can be implemented into routine diagnostic
procedures clinical cutoff values must be defined. Admittedly,
this is a complex issue in which ART potency, genetic barriers
to resistance, weighting factors for individual drug resistance
mutations and their linkages, and the quantity of those minority
variants (in percentages or as absolute HIV RNA copy num-
bers), may have to be taken into consideration.
In summary, we have shown that viruses that harbor K103N
and/or M184V mutations can be detected at low frequencies
in a substantial number of patients with primary HIV-1 infec-
tion lacking detection of drug-resistant viruses by population
sequencing. However, these drug-resistant variants were effi-
ciently suppressed by early ART regimens that contained a ri-
tonavir-boosted PI and 2 NRTIs. Furthermore, virological fail-
ure did not occur in these patients, indicating that ART
regimens with a high genetic barrier to resistance did not select
for these drug-resistant variants from 12 through 48 months.
Our data support the hypothesis that the genetic barrier to
resistance is an important factor with regard to the question
of whether minority drug-resistant HIV-1 variants are associ-
ated with virological failure. Additional studies are necessary
to define the significance of drug-resistant viruses at low fre-
quencies before more-sensitive assays to detect drug-resis-
tant viruses might be implemented into routine diagnostic
procedures.
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